INGREZZA sales guidance for fiscal 2023 reflects expected sales of INGREZZA in tardive dyskinesia only. The guidance range is based upon recent trends and underlying business initiatives underway to help advance the development of the tardive dyskinesia market.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023
- Neurocrine upgraded to Overweight from Equal Weight at Morgan Stanley
- Xenon Pharmaceuticals outlines key milestone opportunities for 2023
- Voyager, Neurocrine enter collaboration to advance multiple gene therapies
- Neurocrine: FDA accepts sNDA for valbenazine